Rare Disease Advocacy

GCA is pleased to announce that we have secured an FDA Patient Listening Session for neuronopathic Gaucher disease (nGD). GCA will be bringing Type 3 families to meet with FDA Regulators in September on the need for approved treatments for nGD. Let us know if you’d like to find out more.